Billingham M E, Carney S, Butler R, Colston M J
Connective Tissue Disease Research, Eli Lilly and Co., Windlesham, Surrey, United Kingdom.
J Exp Med. 1990 Jan 1;171(1):339-44. doi: 10.1084/jem.171.1.339.
A recombinant (r)65-kD protein from Mycobacterium leprae, at levels far in excess of those present in whole mycobacteria, was unable to induce arthritis. Even when combined with a synthetic adjuvant, CP20961, to mimic the peptidoglycan adjuvant component of the mycobacterial cell wall, the r65-kD protein failed to induce arthritis. Pretreatment with as little as 1 microgram r65-kD protein protected rats against arthritis induced by M. tuberculosis, but this r65-kD protein was markedly less able to protect against arthritis induced by the synthetic adjuvant, CP20961, or type II collagen. The r65-kD protein appears, therefore, to produce an antigen-specific protection against arthritis induced by bacterial cell walls containing the 65-kD protein. Such protection can be overcome, however, by arthritogenic T lymphocytes, suggesting that protection occurs by preventing clonal proliferation of autoreactive T lymphocytes that are induced by the adjuvant properties of mycobacterial cell walls. How the r65-kD protein abrogates this particular adjuvant activity, and the nature of the arthritogenic self antigen(s), remain to be elucidated.
来自麻风分枝杆菌的一种重组(r)65-kD蛋白,其水平远远超过完整分枝杆菌中的水平,却无法诱导关节炎。即便与一种合成佐剂CP20961联合使用,以模拟分枝杆菌细胞壁的肽聚糖佐剂成分,r65-kD蛋白仍无法诱导关节炎。用低至1微克的r65-kD蛋白预处理可保护大鼠免受结核分枝杆菌诱导的关节炎,但这种r65-kD蛋白对合成佐剂CP20961或II型胶原诱导的关节炎的保护能力明显较弱。因此,r65-kD蛋白似乎能针对由含65-kD蛋白的细菌细胞壁诱导的关节炎产生抗原特异性保护。然而,这种保护可被致关节炎的T淋巴细胞克服,这表明保护是通过阻止由分枝杆菌细胞壁的佐剂特性诱导的自身反应性T淋巴细胞的克隆增殖而发生的。r65-kD蛋白如何消除这种特定的佐剂活性以及致关节炎自身抗原的性质仍有待阐明。